JPRN-UMIN000005914
Completed
未知
Phase1 clinical study of a single intravenous dose of TRM-1106 in healthy Japanese adult men - TRM-1106 single dose study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Terumo Corporation
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Subject who has been tested positive in a urine drug test or has a history of drug abuse. 2\) Subject who has been tested positive for HBs antigen, HCV antibody or HIV antibody, or who has a positive serological test for syphilis. 3\) Subject who has a history of hypersensitivity or allergy to the study drug (active component and additives) 4\) Subject who currently has or has a history of peptic ulcer; or subject who currently has or has a history of asthma. 5\) Subject with clinically significant disease related to the heart, liver, kidneys, respiratory system, gastrointestinal system, endocrine system, immune system, skin, blood, or psychiatric/nervous system. 6\) Subject who has liver function test values (T\-Bil/D\-Bil, ALT (GPT), AST (GOT), gamma\-GTP and ALP) that exceed the facility's upper limit. However, if the investigator deems that the reason for exceeding the limit is not due to the liver, the subject may be enrolled. 7\) Subject who currently has or have a history of clinically significant bleeding or bleeding tendency. 8\) Subject who has taken other medication or supplements within 1 week prior to study drug administration. 9\) Subject who need to take other medication concurrently while participating in this study. 10\) Subject who smoked tobacco within 1 month prior to study drug administration. 11\) Subject who habitually consume a large amount of alcohol (ingestion of \>\=60 g per day as pure alcohol), or have ingested alcohol within 3 days prior to study drug administration. 12\) Subject who has ingested food products containing St. John's wort within 2 weeks prior to study drug administration. 13\) Subjects who has ingested grapefruit or processed grapefruit products within 1 week prior to study drug administration.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participantsaparoscopic/Minimally Invasive Colorectal SurgeryJPRN-jRCT2071210026Raizer Jeffrey12
Not yet recruiting
Phase 1
Mesenchymal Stem Cell Therapy For Covid 19Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/08/027043eurogen Brain and Spine Institute
Completed
Phase 1
Phase 1 human study for single dose combination of oral Alpha-ketoglutarate (5 grams and 15 grams) & Inj. Sodium Thiosulphate 12.5 grams i.v. against cyanide poisoningCTRI/2010/091/001353Defence R&D Organisation26
Unknown
Phase 1
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222143ONO PHARMACEUTICAL CO.,LTD.42
Completed
Phase 1
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35